

Daniela S Bassãres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1314680/publications.pdf>

Version: 2024-02-01

43
papers

1,791
citations

394421

19
h-index

414414

32
g-index

43
all docs

43
docs citations

43
times ranked

3359
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. <i>Communications Biology</i> , 2021, 4, 370.	4.4	12
2	IKK \hat{I}^2 Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5806.	4.1	1
3	Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 445-460.	4.4	30
4	IKK \hat{I}^2 targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target. <i>Lung Cancer</i> , 2019, 130, 169-178.	2.0	9
5	Where do we aspire to publish? A position paper on scientific communication in biochemistry and molecular biology. <i>Brazilian Journal of Medical and Biological Research</i> , 2019, 52, e8935.	1.5	1
6	Abstract B09: Exploring IKK \hat{I}^2 as an antiangiogenic therapeutic target in KRAS-induced lung cancer. , 2018, , .		0
7	Abstract 5864: Novel anti-BMI-1 therapy in non-small cell lung cancer. , 2018, , .		0
8	Preparation, characterization and in vitro evaluation of \hat{I}^{μ} -polylysine-loaded polymer blend microparticles for potential pancreatic cancer therapy. <i>Journal of Microencapsulation</i> , 2017, 34, 582-591.	2.8	6
9	Development and characterization of miltefosine-loaded polymeric micelles for cancer treatment. <i>Materials Science and Engineering C</i> , 2017, 81, 327-333.	7.3	39
10	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP \hat{I}^{\pm} expression. <i>Science Translational Medicine</i> , 2016, 8, 350ra104.	12.4	45
11	Aurora kinase targeting in lung cancer reduces KRAS-induced transformation. <i>Molecular Cancer</i> , 2016, 15, 12.	19.2	42
12	Abstract 1379: IKK \hat{I}^2 is a potential anti-angiogenic therapeutic target in KRAS-induced lung cancer. , 2015, , .		1
13	Using RNA Interference in Lung Cancer Cells to Target the IKK-NF- \hat{I}^{pB} Pathway. <i>Methods in Molecular Biology</i> , 2015, 1280, 447-458.	0.9	1
14	Akt-dependent Activation of mTORC1 Complex Involves Phosphorylation of mTOR (Mammalian Target of) Tj ETQq0,0,0 rgBT /Overlock 1	3.4	118
15	IKK is a therapeutic target in KRAS-induced lung cancer with disrupted p53 activity. <i>Genes and Cancer</i> , 2014, 5, 41-55.	1.9	31
16	Abstract 533: MicroRNA486-5p is a KRas target involved in promoting cell proliferation in lung cancer. , 2014, , .		0
17	Abstract 4390: Aurora kinases: potential therapeutic targets in K-Ras-induced lung cancer.. , 2013, , .		0
18	Abstract LB-46: C/EBP \hat{I}^{\pm} acts as tumor suppressor in lung cancer by inhibiting the proto-oncogene Bmi-1.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
19	Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. <i>Lung Cancer</i> , 2012, 77, 31-37.	2.0	38
20	Abstract 903: The IKK α kinase is a potential therapeutic target in K-Ras-induced lung cancer. , 2012, , .		0
21	Abstract 4036: Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. , 2012, , .		0
22	RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element. <i>EMBO Journal</i> , 2011, 30, 4059-4070.	7.8	26
23	Requirement of the NF- κ B Subunit p65/RelA for K-Ras α -Induced Lung Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 3537-3546.	0.9	170
24	P2-115: A Causal Relationship between Oncogenic K-Ras Expression and NF-kappaB Activation in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S536-S537.	1.1	0
25	Nuclear factor- κ B and inhibitor of κ B kinase pathways in oncogenic initiation and progression. <i>Oncogene</i> , 2006, 25, 6817-6830.	5.9	627
26	Respiratory Failure Due to Differentiation Arrest and Expansion of Alveolar Cells following Lung-Specific Loss of the Transcription Factor C/EBP β in Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 1109-1123.	2.3	61
27	Block of C/EBP β function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. <i>Journal of Experimental Medicine</i> , 2006, 203, 371-381.	8.5	175
28	Characterisation of a new splice variant of MASK-BP3ARF and MASK human genes, and their expression patterns during haematopoietic cell differentiation. <i>Gene</i> , 2005, 363, 113-122.	2.2	3
29	The SH3 Domain of Alpha Spectrin Binds to Galectin-1 during Erythroid Differentiation.. <i>Blood</i> , 2005, 106, 1666-1666.	1.4	0
30	A Transcriptional Profiling Study of CCAAT/Enhancer Binding Protein Targets Identifies Hepatocyte Nuclear Factor 3 β as a Novel Tumor Suppressor in Lung Cancer. <i>Cancer Research</i> , 2004, 64, 4137-4147.	0.9	66
31	Human leukocyte formin: a novel protein expressed in lymphoid malignancies and associated with Akt. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 365-371.	2.1	46
32	ARHGAP10, a novel human gene coding for a potentially cytoskeletal Rho-GTPase activating protein. <i>Biochemical and Biophysical Research Communications</i> , 2002, 294, 579-585.	2.1	53
33	DNAase I hypersensitive site 3' to the beta-globin gene cluster contains a TAA insertion specific for beta(S)-Benin haplotype. <i>Haematologica</i> , 2002, 87, 246-9.	3.5	2
34	β 2-Spectrin StaB β rbara: a novel frameshift mutation in hereditary spherocytosis associated with detectable levels of mRNA and a germ cell line mosaicism. <i>British Journal of Haematology</i> , 2001, 115, 347-353.	2.5	7
35	Erythrocyte Ankyrin Promoter Mutations Associated with Recessive Hereditary Spherocytosis Cause Significant Abnormalities in Ankyrin Expression. <i>Journal of Biological Chemistry</i> , 2001, 276, 41683-41689.	3.4	26
36	Low frequency of ankyrin mutations in hereditary spherocytosis: Identification of three novel mutations. <i>Human Mutation</i> , 2000, 16, 529-529.	2.5	19

#	ARTICLE	IF	CITATIONS
37	Association of the $\hat{\pm}$ -spectrin R28H mutation with allele $\hat{\pm}$ LELY and with $\hat{\pm}$ I/ $\hat{\pm}$ II domain haplotypes in three Brazilian families. <i>European Journal of Haematology</i> , 2000, 64, 53-58.	2.2	2
38	Novel mutation in the MYOC gene in primary open angle glaucoma patients. <i>Journal of Medical Genetics</i> , 2000, 37, 301-303.	3.2	27
39	Mutation Analysis of the HFE Gene in Brazilian Populations. <i>Blood Cells, Molecules, and Diseases</i> , 1999, 25, 324-327.	1.4	37
40	Presence of allele $\hat{\pm}$ LELY in an Amazonian Indian population. , 1998, 57, 212-214.		3
41	Expression of Spectrin $\hat{\pm}$ I/50 Hereditary Elliptocytosis and Its Association with the $\hat{\pm}$ ^{LELY} Allele. <i>Acta Haematologica</i> , 1998, 100, 32-38.	1.4	8
42	$\hat{\pm}$ â€œSpectrin Campinas: a novel shortened $\hat{\pm}$ â€œchain variant associated with skipping of exon 30 and hereditary elliptocytosis. <i>British Journal of Haematology</i> , 1997, 97, 579-585.	2.5	8
43	Ca ²⁺ -dependent permeabilization of the inner mitochondrial membrane by 4,4â€²-diisothiocyanatostilbene-2,2â€²-disulfonic acid (DIDS). <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1994, 1188, 93-100.	1.0	51